

Utility of Spherical Human Liver Microtissues for Prediction of Clinical Drug-Induced Liver Injury

Proctor, WR², Foster, AJ^{1†}, Vogt, J², Summers, C¹, Middleton, B¹, Pilling, MA¹, Sheinson, D², Kijanska, M³, Ströbel, S³, Haugstetter, J³, Kelm, JM³, Misner, D², Morgan, P¹, Messner, S³, Williams, D¹


¹ Drug Safety and Metabolism, [†]Discovery Sciences, AstraZeneca, Alderley Park, Macclesfield, Cheshire, SK10 4TG, and Cambridge Science Park, Cambridge, Cambridgeshire, CB4 0WG, United Kingdom

² Investigative Toxicology, Department of Safety Assessment, Genentech, Inc. 1 DNA Way, South San Francisco, CA, 94080, USA

³ InSphero AG, Wagistrasse 27, 8952 Schlieren, Switzerland

[†]Corresponding author: Alison Foster, Drug Safety and Metabolism, AstraZeneca, Cambridge Science Park, Cambridge, Cambridgeshire, CB4 0WG, United Kingdom email address: alison.foster2@astrazeneca.com

Supplemental Figure S2:



Supplemental Fig. S2. Time dependent changes in IC_{50} values in hLiMTs for a subset of compounds tested at 5-6 day and 14 day. Lower IC_{50} values were obtained with 21 out of 38 drugs for which cell viability was determined at days 5-6 (striped) and 14 days (solid black). DILI severity category in brackets. A higher IC_{50} values was observed with 1 out of the 38 drugs (flutamide), all other values were unaffected. Data are n=1 or geometric mean of n=2-16.